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Significance statementAlthough mesenchymal stem/stromal cell (MSC) administration is an unproven stem cell therapy approach for COVID‐19 patients, there is a growing demand for new therapies among patients and healthcare workers. Due to preclinical findings and few current clinical data set, MSCs possess remarkable immunomodulatory features, and thus have the potential in recovering the pulmonary microenvironment, intercept pulmonary fibrosis, and cure lung dysfunction in COVID‐19 pneumonia and respiratory distress syndrome. However, it is also noteworthy to point out that there is a good deal of concern about clinics offering unproven stem cell treatments for COVID‐19, and reviewers will be looking for a balanced but critical appraisal of current trials.

1. INTRODUCTION {#sct312784-sec-0003}
===============

The coronavirus disease 2019 (COVID‐19) pandemic, caused by a novel beta coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), possessing a single‐strand, positive‐sense RNA genome (26‐32 kilobases in length),[^1^](#sct312784-bib-0001){ref-type="ref"} is the definition of the greatest health challenge of our times. Since its emergence in Guangdong, Southern China, late last year, the virus has spread to 213 countries in every continent except Antarctica as of late June 2020.[^2^](#sct312784-bib-0002){ref-type="ref"}, [^3^](#sct312784-bib-0003){ref-type="ref"} Cases are still rising, especially in Russia, Brazil, the United States, and the United Kingdom, even though a declining trend was noted in deaths in recent weeks. Countries are struggling with slowing down the spread of the virus by testing and treating patients, quarantining infected citizens, limiting or banning leisure travel, prohibiting large social gatherings, and closing schools. As of June 23, 2020, more than 9.2 million cases have been reported worldwide with around 475 000 deaths.[^3^](#sct312784-bib-0003){ref-type="ref"} The case fatality rate (CFR) varies from 2.3% to 14.8% depending on the demographics of the nation or region, age, severity of the disease, and comorbidities. Overall, the CFR was reported to be around 11% worldwide among COVID‐19‐positive cases, and the ratio of serious or critical cases is around 2%. Older adults between the ages of 70 and 80 years have a CFR of 8.0%, and those aged more than 80 years have a CFR of 14.8%.[^4^](#sct312784-bib-0004){ref-type="ref"} The CFR was reported to 49.0% among critical cases and was significantly high among those with preexisting comorbid conditions---10.5% for cardiovascular disease, 7.3% for diabetes, 6.3% for chronic respiratory disease, 6.0% for hypertension, and 5.6% for cancer.[^4^](#sct312784-bib-0004){ref-type="ref"} In contrast, more than 50% of children (younger than 18 years) experienced mild symptoms or were asymptomatic, with fewer than 6% of children developing severe symptoms.[^5^](#sct312784-bib-0005){ref-type="ref"}

COVID‐19 has an incubation period of 2 to 14 days; the mean incubation period is 5.2 days.[^6^](#sct312784-bib-0006){ref-type="ref"}, [^7^](#sct312784-bib-0007){ref-type="ref"} Although around 30% of infected people are asymptomatic, the onset of illness is characterized by a series of clinical symptoms from mild to severe, including fever (98% of patients), cough, shortness of breath and/or chest pain (76%), and myalgia or fatigue (44%).[^8^](#sct312784-bib-0008){ref-type="ref"} Less common symptoms are sputum production, sore throat, loss of taste and smell, headache, hemoptysis, and diarrhea. Therefore, disease stage is classified according to the patient\'s clinical symptoms and laboratory findings as (a) *mild type*: mild clinical symptoms without pneumonia; (b) *common type*: fever, respiratory tract and other symptoms with pneumonia; (c) *severe type*: respiratory distress (respiratory rate is higher than 30 times per minute; in resting state, oxygen saturation is lower than 93%; partial pressure of oxygen \[PaO~2~\] to fraction of inspired oxygen \[FiO~2~\] ratio lower than 300 mmHg); (d) *critical type*: respiratory failure requiring mechanical ventilation, shock, and other organ failure requiring intensive care unit (ICU) monitoring and treatment.[^9^](#sct312784-bib-0009){ref-type="ref"} In addition, patients with acute cardiac injury present with tachycardia or bradycardia. Critically ill individuals may also have acidosis and increased lactate.[^6^](#sct312784-bib-0006){ref-type="ref"}

No specific antiviral therapeutic agents or vaccines for COVID‐19 have been proven to be effective so far. Several therapies, such as ribavirin, remdesivir, favipiravir, and oseltamivir, are under investigation,[^4^](#sct312784-bib-0004){ref-type="ref"}, [^10^](#sct312784-bib-0010){ref-type="ref"} but the antiviral efficacy of these drugs is not yet known. The supportive approach includes corticosteroids, antibiotics, anticoagulants, and oxygen therapy. Recently, convalescent plasma therapy for COVID‐19 has been under consideration to prove its safety and efficacy. Promising results (32 participants) and 48 ongoing trials were accumulated in a Cochrane analysis.[^11^](#sct312784-bib-0011){ref-type="ref"}

As defined below, cytokine storm (high serum levels of GSCF, interferon‐γ inducible protein 10 \[IP‐10\], monocyte chemoattractant protein 1 \[MCP‐1\], macrophage inflammatory protein \[MIP\]‐1A, interleukin \[IL\]‐2, IL‐6, IL‐7, and tumor necrosis factor \[TNF\]) in COVID‐19‐infected patients results in pulmonary edema, dysfunction of air exchange, acute respiratory distress syndrome (ARDS), and acute cardiac injury and may lead to death. As mesenchymal stem cells (MSCs) possess many remarkable immunomodulatory and extracellular matrix remodeling effects through secretion of several types of cytokines, growth factors, and tissue mediators, they modulate the cytokine storm or balance immune responses as one of their therapeutic effects in recovering the pulmonary microenvironment, protecting alveolar epithelial cells, intercepting pulmonary fibrosis, and curing lung dysfunction and COVID‐19 pneumonia. In this review, we endeavored to discuss the potentials of MSC‐based cell therapies in the light of current literature obtained from both preclinical and clinical studies.

2. DIAGNOSIS AND INFLAMMATORY PROFILE OF PATIENTS WITH COVID‐19 {#sct312784-sec-0004}
===============================================================

The diagnosis of COVID‐19 is performed by the detection of the virus in respiratory secretions (throat, nasopharynx, sputum, and endotracheal aspirates and bronchoalveolar lavage) by sensitive antigen tests such as polymerase chain reaction assay, even though the testing efficiency is around 60% to 70% in sputum and nasal swab samples.[^12^](#sct312784-bib-0012){ref-type="ref"} Besides common radiographic tests such as x‐ray and computed tomography (CT) imaging, more sophisticated serologic and genomic tests are also available including the full genome analysis by next‐generation sequencing.[^13^](#sct312784-bib-0013){ref-type="ref"} As summarized in Table [1](#sct312784-tbl-0001){ref-type="table"}, blood test findings include normal/low leukocyte counts with high C‐reactive protein (CRP). There may be lymphopenia; fewer than 1000 lymphocytes has been associated with severe disease. The platelet count is usually normal or slightly low. The CRP and erythrocyte sedimentation rate are generally elevated; however, procalcitonin levels are usually normal. A high procalcitonin level may imply a bacterial coinfection. The aspartate transaminase (AST) and alanine transaminase (ALT), prothrombin time, creatinine, [d]{.smallcaps}‐dimer, creatinine phosphokinase, and lactate dehydrogenase may be elevated, and high levels are associated with severe disease.[^14^](#sct312784-bib-0014){ref-type="ref"}, [^15^](#sct312784-bib-0015){ref-type="ref"} CT chest scans are usually abnormal even in those with no symptoms or mild disease. However, starting from the common cases, CT imaging shows infiltrates, ground‐glass opacities, and subsegmental consolidation. It may also have abnormal results in asymptomatic patients or patients with no clinical evidence of lower respiratory tract involvement. In fact, abnormal CT scans have been used to diagnose COVID‐19 in suspected virus‐negative cases; many of these patients become positive on repeat testing.[^16^](#sct312784-bib-0016){ref-type="ref"}

###### 

The immunological, serological, and histopathological profile of patients with COVID‐19

+-------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+
| Immunopathology                                                                                                                           | Serum/blood tests                                                                                                                                                                                                                                                                                                      | Lung histopathology                                                    |
+:==========================================================================================================================================+:======================================================================================================================================================================================================================================================================================================================:+:======================================================================:+
| IFN‐γ ↑, IL‐1β ↑, IP‐10 ↑, MCP‐1 ↑, GCSF ↑, IL‐2 ↑, IL‐6 ↑, IL‐7 ↑, IL‐8 ↑, IL‐9 ↑, IL‐10 ↑, IL‐17 ↑, MIP‐1α ↑, MCP‐1 ↑, IP‐10 ↑, TNF‐α ↑ | AST ↑, ALT ↑, LDH ↑, CPK ↑, creatinine ↑, CRP ↑, ESR ↑, γ‐GT ↑, α‐HBDH ↑, [d]{.smallcaps}‐dimer ↑, total bilirubin ↑, ferritin ↑, prothrombin time ↑, cardiac troponin ↑, procalcitonin ↑, albumin ↓, hemoglobin ↓, eosinophils ↓, basophils ↓, neutrophils ↑, monocytes ↓, CD14^+^ CD16^+^ monocytes ↑, lymphocytes ↓ | Atypical enlarged pneumocytes and/or desquamation of pneumocytes       |
|                                                                                                                                           |                                                                                                                                                                                                                                                                                                                        |                                                                        |
|                                                                                                                                           |                                                                                                                                                                                                                                                                                                                        | Hyaline membrane formation                                             |
|                                                                                                                                           |                                                                                                                                                                                                                                                                                                                        |                                                                        |
|                                                                                                                                           |                                                                                                                                                                                                                                                                                                                        | Cellular or proteinaceous exudates                                     |
|                                                                                                                                           |                                                                                                                                                                                                                                                                                                                        |                                                                        |
|                                                                                                                                           |                                                                                                                                                                                                                                                                                                                        | Alveolar hemorrhage                                                    |
|                                                                                                                                           |                                                                                                                                                                                                                                                                                                                        |                                                                        |
|                                                                                                                                           |                                                                                                                                                                                                                                                                                                                        | Fibrinoid necrosis of small vessels                                    |
|                                                                                                                                           |                                                                                                                                                                                                                                                                                                                        |                                                                        |
|                                                                                                                                           |                                                                                                                                                                                                                                                                                                                        | Multinucleated syncytial cells                                         |
|                                                                                                                                           |                                                                                                                                                                                                                                                                                                                        |                                                                        |
|                                                                                                                                           |                                                                                                                                                                                                                                                                                                                        | Interstitial accumulation of mononuclear cells (monocytes and T cells) |
|                                                                                                                                           |                                                                                                                                                                                                                                                                                                                        |                                                                        |
|                                                                                                                                           |                                                                                                                                                                                                                                                                                                                        | Endothelial dysfunction associated with apoptosis                      |
+-------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+------------------------------------------------------------------------+

*Note:* The degree of elevation (↑) or decline (↓) and histopathological changes vary by the severity of patient\'s clinical status from mild to severe cases of acute respiratory distress syndrome.

Abbreviations: α‐HBDH, α‐hydroxybutyrate dehydrogenase; γ‐GT, gamma‐glutamyl transpeptidase; ALT, alanine transaminase; AST, aspartate transaminase; CPK, creatine phosphokinase; CRP, C‐reactive protein; ESR, erythrocyte sedimentation rate; GCSF, granulocyte‐colony stimulating factor; IFN‐γ, interferon gamma; IL, interleukin; IP‐10, IFN‐γ inducible protein 10 (also known as CXC‐chemokine ligand 10); MCP‐1, monocyte chemoattractant protein 1 (also known as CC‐chemokine ligand 2); LDH, lactic acid dehydrogenase; MIP‐1α, macrophage inflammatory protein 1α (also known as CC‐chemokine ligand 3); TNF‐α, tumor necrosis factor‐α.

According to the laboratory tests published so far, in a subset of patients with COVID‐19, clinical progress is associated with an activation of an inflammatory cascade, called "cytokine storm syndrome," which is mainly due to activated T‐helper 1 (Th1) and T‐helper 17 (Th17) cell responses.[^17^](#sct312784-bib-0017){ref-type="ref"}, [^18^](#sct312784-bib-0018){ref-type="ref"} It is a diverse set of conditions unified by a clinical phenotype of systemic inflammation, multiorgan failure, and hyperferritinemia[^19^](#sct312784-bib-0019){ref-type="ref"} and is associated with a wide variety of virus infections, such as severe acute respiratory coronaviruses (including SARS‐CoV‐2), influenza virus, and dengue virus, and noninfectious diseases.[^20^](#sct312784-bib-0020){ref-type="ref"} Some patients with COVID‐19 progress to this hyperinflammatory condition, often with pulmonary involvement resembling the secondary hemophagocytic syndrome, which is commonly triggered by viral infections.[^21^](#sct312784-bib-0021){ref-type="ref"} This systemic hyperinflammation results in inflammatory lymphocytic and monocytic infiltration of the lung and heart, causing ARDS and cardiac failure. Huang et al[^8^](#sct312784-bib-0008){ref-type="ref"} noted that patients with COVID‐19 both in the ICU and not requiring the ICU demonstrated higher cytokine profiles compared with healthy adults, characterized by increased IL‐1β, IL‐2, IL‐7, IL‐8, IL‐9, IL‐10, IL‐17, granulocyte‐colony stimulating factor (GCSF), IP‐10, MCP‐1, MIP‐1α, TNF‐α, and some growth factors such as platelet‐derived growth factor and vascular endothelial growth factor (VEGF)[^8^](#sct312784-bib-0008){ref-type="ref"} (Table [1](#sct312784-tbl-0001){ref-type="table"}). Huang et al further reported that plasma concentrations of IL‐2, IL‐7, IL‐10, GCSF, IP‐10, MCP‐1, MIP‐1α, and TNF‐α were higher in patients in the ICU than in patients not in the ICU. On the other hand, plasma levels of IL‐5, IL‐12p70, IL‐15, eotaxin, and RANTES were found to be comparable between healthy adults and infected patients. Predictors of mortality in a recent retrospective study of 150 confirmed COVID‐19 cases in Wuhan, China, included elevated IL‐6.[^22^](#sct312784-bib-0022){ref-type="ref"} Taken together, cytokine profiles of patients seem to lead to mortality that is directly related to virus‐driven hyperinflammation.[^23^](#sct312784-bib-0023){ref-type="ref"} As demonstrated in patients with severe acute respiratory syndrome (SARS) more than 15 years ago, elevated levels of T‐helper cell‐originated proinflammatory cytokines, that is, interferon (IFN)‐γ, IL‐1B, IL‐6, IL‐12, IP‐10, neutrophil‐originated chemokine IL‐8, and MCP‐1, were associated with pulmonary inflammation and extensive lung damage.[^24^](#sct312784-bib-0024){ref-type="ref"} More recently, Mahallawi et al reported marked increases in the concentrations of IFN‐γ, TNF‐α, IL‐15, and IL‐17 in patients with Middle East respiratory syndrome (MERS) coronavirus compared with controls.[^25^](#sct312784-bib-0025){ref-type="ref"} Secretion of such cytokines and chemokines attracts immune cells, notably monocytes and T lymphocytes (CD4+ T cells), but not neutrophils, from the blood into the infected site. Pulmonary recruitment of immune cells from the blood and the infiltration of lymphocytes into the airways may explain the lymphopenia and increased neutrophil‐lymphocyte ratio seen in around 80% of patients with SARS‐CoV‐2 infection.

Besides the cytokine storm, COVID‐19‐related clinical manifestations reflect that patients develop lymphocytic endotheliitis as evidenced by the impairment of many organs, including kidney, heart, small intestine, and lungs.[^26^](#sct312784-bib-0026){ref-type="ref"} Therefore, COVID‐19 pathogenesis in the endothelial cells causes a vascular disease state during which 89% of hospitalized patients showed subsegmental vascular enlargement on their initial CT scans.[^27^](#sct312784-bib-0027){ref-type="ref"} Studies have also reported evidence of a COVID‐19‐associated coagulopathy. It has been shown that 90% of patients with pneumonia had increased coagulation activity, marked by elevated [d]{.smallcaps}‐dimer, a fibrin degradation thromboembolic marker[^28^](#sct312784-bib-0028){ref-type="ref"} predicting a poor prognosis in COVID‐19.

3. ARDS IN COVID‐19 {#sct312784-sec-0005}
===================

ARDS, by definition, is a clinical state characterized by an acute presentation of severe and refractory hypoxemia, decreased airway compliance, microscopic evidence of diffuse alveolar damage, and bilateral pulmonary infiltrates excluding cardiac‐related edema.[^29^](#sct312784-bib-0029){ref-type="ref"} Respiratory failure from ARDS has been reported as the leading cause of mortality in COVID‐19 cases.[^22^](#sct312784-bib-0022){ref-type="ref"} Around 10% to 20% of patients with severe COVID‐19 may develop shortness of breath, frequently in the second week of the disease, which might be accompanied by or progress to hypoxemia.[^8^](#sct312784-bib-0008){ref-type="ref"} The mean period from onset of symptoms to dyspnea was reported as 5 days, hospitalization 7 days, and the onset of ARDS 8 to 9 days.[^14^](#sct312784-bib-0014){ref-type="ref"} Respiratory damage will inevitably progress into ARDS, defined as PaO~2~/FiO~2~ lower than 300 mmHg, during days 8 to 14 of the illness, as well as resulting in noncardiogenic pulmonary edema and mechanical ventilation.[^8^](#sct312784-bib-0008){ref-type="ref"}, [^30^](#sct312784-bib-0030){ref-type="ref"}

ARDS constitutes an acute hypoxemic respiratory failure that originates mainly from an increase in lung endothelial and epithelial permeability, which result in outflow of fluid into alveoli, leading to noncardiogenic pulmonary edema and decreased arterial oxygenation. Damage to the lung parenchyma results from multiple mechanisms, including direct injury by the inflaming agent (eg, bacteria and their products, viral invasion, and acid injury after aspiration), by harm in resulting from hyperactivation of the immune system, and by mechanical stretch‐induced damage caused by mechanical ventilation.[^31^](#sct312784-bib-0031){ref-type="ref"} The pathologic features of ARDS in alveoli and their microenvironment in COVID‐19 greatly resemble those seen in SARS and MERS infections,[^32^](#sct312784-bib-0032){ref-type="ref"}, [^33^](#sct312784-bib-0033){ref-type="ref"} including uni/bilateral diffuse alveolar parenchyma damage with cellular fibromyxoid exudates, desquamation of pneumocytes, and hyaline membrane formation[^34^](#sct312784-bib-0034){ref-type="ref"} (Table [1](#sct312784-tbl-0001){ref-type="table"}). Mononuclear infiltrates---predominantly by lymphocytes---are frequently seen in interalveolar septa. Multinucleated syncytial cells with enlarged alveolar cells characterized by large nuclei, granular cytoplasm, and prominent nucleoli are identified in the intra‐alveolar septa,[^34^](#sct312784-bib-0034){ref-type="ref"} directly presenting the viral cytopathic changes. There may be no obvious intranuclear or intracytoplasmic viral inclusions.

4. MESENCHYMAL STEM CELLS {#sct312784-sec-0006}
=========================

MSCs are fibroblast‐like precursors resident in most adult and neonatal tissues. MSCs are isolated based on their ability to adhere to plastic culture dishes, and they are capable of proliferating by in vitro passaging. They are characterized by their capacity to differentiate into cells of mesodermal origin, such as adipocytes, chondroblasts, and osteoblasts,[^35^](#sct312784-bib-0035){ref-type="ref"} and they possess certain cell surface molecules: CD73, CD90, and CD105.[^36^](#sct312784-bib-0036){ref-type="ref"} Although much debate remains as to how to define such a wide population of cells, it is apparent that some populations of MSCs are capable of demonstrating stem cell functions both in vivo and in vitro.[^37^](#sct312784-bib-0037){ref-type="ref"} In addition to their stem or progenitor properties, MSCs have also been shown to possess extensive immunoregulatory abilities and are capable of manipulating both adaptive and innate immune responses.[^38^](#sct312784-bib-0038){ref-type="ref"} Clues obtained from both preclinical and clinical studies have demonstrated that MSCs actively interact with components of the innate immune system and that, through these interactions, they display both anti‐inflammatory and proinflammatory effects.[^39^](#sct312784-bib-0039){ref-type="ref"} Paracrine effects of MSCs were reported several years ago by Haynesworth et al,[^40^](#sct312784-bib-0040){ref-type="ref"} who demonstrated that MSCs synthesize and secrete a wide range of growth factors and cytokines such as VEGF, fibroblast growth factor (FGF), MCP‐1, hepatocyte growth factor (HGF), IGF‐I, stromal cell‐derived factor 1, and thrombopoietin, which exert actions on their microenvironment. Therefore, MSCs constitute an important resource for cellular therapy. They have been the subject of clinical trials as a cellular pharmaceutic agent since 1995[^41^](#sct312784-bib-0041){ref-type="ref"} and have become the central point of the most clinically studied experimental cell therapy in the world.[^42^](#sct312784-bib-0042){ref-type="ref"}, [^43^](#sct312784-bib-0043){ref-type="ref"} However, only a small number of studies investigating the effects of MSCs in preclinical models of respiratory virus infections were published so far (reviewed by Khoury et al[^44^](#sct312784-bib-0044){ref-type="ref"}), and no established animal model for coronavirus respiratory infection exists to investigate the effects of MSC administration in nonhuman controlled experiments. Severe acute respiratory coronavirus replication was observed in *STAT1* ^−/−^ knockout mice after intranasal infection, but this model failed to show clinical signs of pulmonary disease as seen in human.[^45^](#sct312784-bib-0045){ref-type="ref"}

5. MSC SOURCES {#sct312784-sec-0007}
==============

MSCs can be isolated from various tissue sources. The selection of the source is based on their logistical, practical, and in vitro characteristics. Currently, the main sources of MSCs are bone marrow, umbilical cord stroma, adipose tissue, and dental pulp.

5.1. Bone marrow {#sct312784-sec-0008}
----------------

Bone marrow mesenchymal stem cells (BM‐MSCs) are multipotent cells that are able to differentiate into mesodermal lineage.[^46^](#sct312784-bib-0046){ref-type="ref"} They are isolated from bone marrow aspirates and subsequently expand in vitro. They have been shown to express a variety of cell surface markers, including CD44, CD73, CD105, and CD146, but they lack hemopoietic markers CD11b, CD14, CD34, and CD45.[^47^](#sct312784-bib-0047){ref-type="ref"} BM‐MSCs have inherently low immunogenicity because of the low expression of major complex of histocompatibility (MHC) class I and the lack of MHC class II expression. They also do not express the costimulatory molecules CD40 and CD80. They inhibit T‐lymphocyte proliferation and activation in response to alloantigens.[^48^](#sct312784-bib-0048){ref-type="ref"} Collectively, the low immunogenicity properties of BM‐MSCs and the interactions between BM‐MSCs and immune cells provide BM‐MSC‐mediated induction of tolerance that could be therapeutic for modulation of inflammation.

5.2. Umbilical cord {#sct312784-sec-0009}
-------------------

Human umbilical cord stroma, which is known as Wharton\'s jelly, is a rich source of primitive mesenchymal stromal cells (UC‐MSCs or WJ‐MSCs). UC‐MSCs are multipotent cells that can be differentiated into mesodermal as well as to neuronal lineages.[^49^](#sct312784-bib-0049){ref-type="ref"} UC‐MSCs are harvested from the umbilical cord stroma using mechanical or enzymatic techniques[^50^](#sct312784-bib-0050){ref-type="ref"} and subsequently expanded in vitro. However, an explant culture system provides a more physiologic milieu to harvest intact cells compared with enzymatic isolation.[^51^](#sct312784-bib-0051){ref-type="ref"} UC‐MSCs are positive for CD73, CD90, CD105, and human leukocyte antigen (HLA) class I and negative for CD45 and HLA‐DR.[^36^](#sct312784-bib-0036){ref-type="ref"}, [^52^](#sct312784-bib-0052){ref-type="ref"} They display immunosuppressive potential by cell‐cell contact with activated T cells,[^53^](#sct312784-bib-0053){ref-type="ref"} and they efficiently suppress the proliferation and cytokine production of a subset of circulating T cells.[^54^](#sct312784-bib-0054){ref-type="ref"} Moreover, UC‐MSCs produce large amounts of tolerogenic IL‐6, transforming growth factor (TGF)‐β, and VEGF‐1.[^55^](#sct312784-bib-0055){ref-type="ref"} Given that UC‐MSCs exhibit many unique features, involving the regulation of both innate and adaptive immune responses,[^56^](#sct312784-bib-0056){ref-type="ref"} they stand as the most widely used and first‐selected allogeneic MSCs in several immunocompromised diseases.[^57^](#sct312784-bib-0057){ref-type="ref"}, [^58^](#sct312784-bib-0058){ref-type="ref"}

5.3. Adipose tissue {#sct312784-sec-0010}
-------------------

Several studies revealed that adipose tissues contain MSCs, termed adipose tissue‐derived stem cells (ADSCs). They are preferentially located in the stromal vascular fraction of isolated adipose explants. In conditional cultures, ADSCs exhibit a multipotent differentiation capacity into cell types originated from three germ layers.[^59^](#sct312784-bib-0059){ref-type="ref"} ADSCs express CD44, CD73, CD90, and CD105 and are negative for CD31 and CD45.[^60^](#sct312784-bib-0060){ref-type="ref"} ADSCs can induce proliferation of IL‐10‐producing regulatory B cells that regulate the immune system by anti‐inflammatory potential.[^61^](#sct312784-bib-0061){ref-type="ref"} Therefore, ADSCs can be used in the treatment of diverse immune‐related disorders, including graft‐vs‐host disease.[^62^](#sct312784-bib-0062){ref-type="ref"} As the isolation of autologous ADSCs is relatively simple and less invasive compared with BM‐MSCs, they have been the first choice in many trials. However, ADSCs still exhibited only moderate benefits in clinical trials.

5.4. Dental pulp {#sct312784-sec-0011}
----------------

Dental pulp MSCs (DP‐MSCs), primarily isolated from the dental pulp,[^63^](#sct312784-bib-0063){ref-type="ref"} can also be isolated from deciduous teeth, apical papilla, periodontal ligament, dental follicles, and gingiva.[^64^](#sct312784-bib-0064){ref-type="ref"} DP‐MSCs express CD29, CD73, CD90, and CD105 and do not express the hematopoietic stem cell markers CD11b, CD14, CD34, CD45, and HLA‐DR. They have the capacity to differentiate into mesodermal lineage under certain conditions in vitro.[^36^](#sct312784-bib-0036){ref-type="ref"} However, DP‐MSCs also express stemness‐related markers similar to embryonic stem cells, such as Oct‐3/4, Nanog, and Sox‐2.[^65^](#sct312784-bib-0065){ref-type="ref"} Like MSCs from other tissues, DP‐MSCs also have a strong immunomodulatory ability with a higher suppression rate of T‐lymphocyte growth capacities.[^66^](#sct312784-bib-0066){ref-type="ref"} Moreover, DP‐MSCs can suppress lymphocyte proliferation and increase the number of regulatory T cells and IL‐10 while decreasing IL‐4 and IFN‐γ levels.[^67^](#sct312784-bib-0067){ref-type="ref"} Therefore, dental pulp is considered a novel MSC source to use for the treatment of autoimmune and inflammatory diseases.

6. IMMUNOREGULATORY FEATURES OF MSCS {#sct312784-sec-0012}
====================================

Studies suggest that the tissue from which MSCs originate determines their capacity to differentiate and their immunoregulatory potential.[^68^](#sct312784-bib-0068){ref-type="ref"} However, variations in the range and functional status of immune cells in the inflammation site also affect the ability of MSCs to regulate inflammation. MSCs express receptors for chemokines, through which they sense and migrate toward inflammatory signals, such as complement factors C3a and C5a, which are released by damaged tissues[^69^](#sct312784-bib-0069){ref-type="ref"} and serve as chemoattractants for MSCs. An active state of inflammation is often subject to dynamic changes, which can modify the immunologic properties of MSCs. Thus, anatomic location and inflammatory state are critical determinants of the immunoregulatory properties of MSCs and might govern the therapeutic potential of these cells in inflammatory diseases.

Several kinds of innate immune cells, like neutrophils, mast cells, macrophages, myeloid‐derived suppressor cells, dendritic cells, and natural killer (NK) cells, exist at inflammation sites and can be synchronized by MSCs, whereas variations in chemokine expression can dictate the MSC functions. For instance, macrophages exist in a spectrum of different phenotypes as proinflammatory (M1) or anti‐inflammatory (M2), both of which expresses their functional states and are associated with distinct pathologies. MSCs facilitate monocyte‐to‐macrophage transition, potentiate their microbicidal responses, skew naïve macrophages to a M1 state, attenuate already activated M1 macrophages, and enhance M2 activation. This polarization of macrophages from M1 to M2 state is mediated by the production of MSC‐derived immunosuppressive molecules and metabolites, such as prostaglandin E2 (PGE~2~)[^70^](#sct312784-bib-0070){ref-type="ref"} and TNF‐stimulated gene 6 protein (TSG6).[^71^](#sct312784-bib-0071){ref-type="ref"} Elucidation of key monocyte and macrophage metabolic programs in monocyte‐MSC, M1‐MSC, and M2‐MSC cocultures indicated changes in glucose transporter‐1 expression/glucose uptake, indoleamine 2,3‐dioxygenase (IDO) 1 protein/activity, SIRTUIN1, and alterations in activated‐protein kinase and mammalian target of rapamycin activity, reflecting MSC‐instructed metabolic shifts.[^70^](#sct312784-bib-0070){ref-type="ref"} MSCs could also inhibit the infiltration of macrophages, monocytes, and neutrophils into sites of inflammation in a TSG6‐dependent mode. This mechanism is critical to the ability of MSCs to alleviate acute lung injury.[^72^](#sct312784-bib-0072){ref-type="ref"} Inflammatory cytokines that control chemokine production can provoke MSCs to recruit monocytes, macrophages, and neutrophils to their proximity. Similarly, inflammation can induce the expression of IDO by MSCs, with immunosuppressive consequences on myeloid cell migration. These findings elucidate the complexity of MSC‐innate immune cell interactions in an inflammatory microenvironment and the difficulty in predicting whether the immunomodulatory response of MSCs tend to be positive or negative.

The immunosuppression cascade starts with the induction of MSCs by IFN‐γ, which, combined with either TNF or IL‐1, costimulates the production of CC‐chemokine receptor 5 and CXC‐chemokine receptor 3 ligands, including CC‐chemokine ligand 5, CXC‐chemokine ligand (CXCL) 9, CXCL10, and CXCL11, all of which attract T cells to the proximity of MSCs (extensively reviewed by Shi et al[^68^](#sct312784-bib-0068){ref-type="ref"}). Subsequently, MSCs in humans suppress the proliferation and activity of T cells in their vicinity by expressing IDO (Figure [1](#sct312784-fig-0001){ref-type="fig"}). Immunoregulation by MSCs is also mediated by the production of cytokines (TGF‐β and IL‐6), growth factors (HGF and leukemia inhibitory factor), and anti‐inflammatory mediators (PGE~2~, TSG6, heme oxygenase 1, galectins, and extracellular vesicles \[EVs\]). These factors inhibit the proliferation and function of proinflammatory immune Th1 and/or Th17 cells, proinflammatory M1 macrophages, neutrophils, NK cells, and B cells and enhance the numbers of anti‐inflammatory immune cells, including anti‐inflammatory M2 macrophages, regulatory T cells, and regulatory B cells. Anti‐inflammatory immune cells can further suppress the activity and functions of proinflammatory cells and thus promote tissue reparation and regeneration. On the other hand, transplanted MSCs can be attacked by factors of the complement system, complement‐activated neutrophils, and perforin‐positive cytotoxic cells, stimulating them to undergo apoptosis. Apoptotic MSCs can then be engulfed by macrophages so they induce the phagocytes to express IDO, with immunosuppressive consequences.

![Interactions of MSCs with their microenvironment after inflammation is triggered. A, MSCs produce TNF, IFN‐γ, and IL‐1 in the proinflammatory state and consequently acquire an activated state that stimulates two main consecutive events. B, Recruitment of T cells to the vicinity of MSCs by the secretion of CCL5, CXCL9, CXCL10, CXCL11, which then bind to their de novo synthesis of specific receptors (CXCR3 and CCR5). C, Suppression of the proliferation and activity of T cells in their vicinity by IDO secretion. Immunosuppression by MSCs is also mediated by the production of TGF‐β, IL‐6, HGF, leukemia inhibitory factor (LIF), PGE~2~, TSG6, and HO1 exhibited by several sizes of extracellular vesicles. D, E, These factors stimulate the proliferation of anti‐inflammatory immune cells (anti‐inflammatory M2 macrophages, regulatory T cells, and B cells) while inhibiting the proliferation and function of proinflammatory immune cells (Th1 and/or Th17 cells, proinflammatory M1 macrophages, neutrophils, NK cells, and B cells). F, Transplanted MSCs may be assaulted by complement factors, complement‐activated neutrophils, and cytotoxic cells, all of which will induce them to undergo apoptosis. CCL5, CC‐chemokine ligand 5; CCR5, CC‐chemokine receptor 5; CXCL, CXC‐chemokine ligand; CXCR3, CXC‐chemokine receptor 3; HGF, hepatocyte growth factor; HO1, heme oxygenase 1; IDO, indoleamine 2,3‐dioxygenase; IFN, interferon; IL, interleukin; LIF, leukemia inhibitory factor; MSC, mesenchymal stem cell; NK, natural killer; PGE~2~, prostaglandin E2; TGF, transforming growth factor; Th1, T‐helper 1; Th17, T‐helper 17; TNF, tumor necrosis factor; TSG6, TNF‐stimulated gene 6 protein](SCT3-9999-na-g001){#sct312784-fig-0001}

Interestingly, tissue‐resident MSCs may not be as effective as transplanted MSCs in restoring immunologic homeostasis in damaged tissues.[^68^](#sct312784-bib-0068){ref-type="ref"} One possible explanation for this difference is that in vitro cultured and expanded MSCs are often administered in large quantities (typically 1 × 10^6^ cells per kilogram of body weight) compared with a normal concentration of less than 0.05% stromal cells among the entire population of bone marrow cells.[^73^](#sct312784-bib-0073){ref-type="ref"} Another possible scenario is that MSCs may be changing their immune properties during in vitro expansion.

7. ANTIFIBROTIC (EXTRACELLULAR MATRIX REMODELING) PROPERTIES OF MSCs {#sct312784-sec-0013}
====================================================================

Healthy tissues can be damaged after acute or chronic stimuli, such as mechanical or chemical injuries, infections, or autoimmune reactions. Dead or damaged cells and extracellular matrix (ECM) elements are replaced by the formation of scar tissue composed of stiff cross‐linking collagen fibers mostly synthesized by myofibroblasts; thus, this process ensures organ functionality, although usually of inferior quality. In the last stage or as an alternative path of the repair process, fibrosis, also known as fibrotic scarring, replaces scarred parenchymal tissue to a great extent, leading to considerable tissue remodeling and the formation of permanent scar tissue. However, unrestricted fibrosis leads to substantial remodeling of the ECM with pathologic features. In most cases, this process leads to perturbed organ function and death. It has been demonstrated that matrix metalloproteinases (MMPs, a group of proteolytic enzymes that are capable of degrading all types of extracellular matrix proteins: MMP3, MMP6, and MMP9) and tissue inhibitor of matrix metalloproteinases (TIMPs) TIMP1 and TIMP3 decreased after MSC treatment of pressure overload hypertrophy.[^74^](#sct312784-bib-0074){ref-type="ref"} Moreover, administration of MSCs prevented irradiation‐induced lung fibrosis by reducing production of inflammatory cytokines, proliferation of fibroblasts, and accumulation of collagen.[^75^](#sct312784-bib-0075){ref-type="ref"} They also limit the fibrotic response by reducing myofibroblast differentiation from epithelial cells and fibroblasts.[^76^](#sct312784-bib-0076){ref-type="ref"} Thus, MSCs are considered as critical elements in ECM remodeling after tissue damage; therefore, they represent a therapeutic tool in recovering normal tissue functions in fibrosis.

8. MSC‐DERIVED EVS {#sct312784-sec-0014}
==================

Recent studies suggest that the signals responsible for the therapeutic effects of MSCs are at least partially linked to the production of EVs. Simply, EVs are small, round packages Type‐I alveolar cell of secretory products enclosed by a phospholipid bilayer membrane, which carry several bioactive components.[^77^](#sct312784-bib-0077){ref-type="ref"} Although confusion on the nomenclature of EVs exists in the literature, EVs are currently classified into exosomes, microvesicles, and apoptotic bodies according to their cellular origin.[^78^](#sct312784-bib-0078){ref-type="ref"} EVs encapsulate cargo molecules, including proteins, microRNA, and mRNAs, from their cell of origin.[^79^](#sct312784-bib-0079){ref-type="ref"} Furthermore, they carry several types of membrane proteins, including glycosylated adhesion molecules and receptors, and lipids.[^80^](#sct312784-bib-0080){ref-type="ref"}, [^81^](#sct312784-bib-0081){ref-type="ref"} A huge number of studies demonstrated that MSCs could modulate immune response by cell‐to‐cell contact, secretion of soluble factors, induction of anergy, apoptosis, and regulatory immune cells to induce anti‐inflammatory signals and immune tolerance states.[^82^](#sct312784-bib-0082){ref-type="ref"}, [^83^](#sct312784-bib-0083){ref-type="ref"} Among those, MSC‐derived EVs play a role in the regulation of the inflammatory response by increasing the level of anti‐inflammatory cytokines and decrease proinflammatory cytokines, which opens avenues to promising immune therapy approaches. A recent study demonstrated that MSC‐derived EV cargoes comprised immunomodulatory cytokines such as IFN‐γ‐induced protein 10, MIP‐1β, IL‐8, chemokine growth‐regulated oncogene, and TIMP1.[^84^](#sct312784-bib-0084){ref-type="ref"} Moreover, cytokines, including intercellular adhesion molecule‐1, basic FGF, CD105, and a microRNA (miR210), which has roles in vascular repair signaling, were also identified from MSC‐derived EVs. However, there are several challenges and potential risk factors that should still be considered, including the difficulties of harvesting and purifying EVs from various types of samples (culture media, serum, urine, milk, and other potential sources).[^85^](#sct312784-bib-0085){ref-type="ref"} The safety, immunogenic response potency, and optimal doses of EVs are still largely unknown. There are a limited number of clinical studies employing EV‐based therapies focused on neurologic, cardiovascular, liver, kidney, and skin diseases ([ClinicalTrials.gov](http://ClinicalTrials.gov)). Nonetheless, MSC‐EV‐based therapies present fundamental advances in terms of potential cell‐free therapy options in the future.

9. MSC‐DRIVEN MITOCHONDRIAL TRANSFER {#sct312784-sec-0015}
====================================

MSCs have been reported to present protective effects in several preclinical experimental models of ARDS, including the ex vivo human lung perfusion model.[^86^](#sct312784-bib-0086){ref-type="ref"}, [^87^](#sct312784-bib-0087){ref-type="ref"}, [^88^](#sct312784-bib-0088){ref-type="ref"} However, the mechanism of this effect was largely unknown. Initially, Islam et al showed that MSCs could transfer mitochondria to impaired alveolar epithelial cells by a connexin‐43--dependent mechanism.[^89^](#sct312784-bib-0089){ref-type="ref"} This mitochondrial transfer resulted in increased alveolar ATP concentrations in injured mouse epithelial cells. This effect reduced the endotoxin‐induced alveolar injury and increased survival. More recent studies demonstrated that mitochondrial transfer from MSCs to macrophages[^90^](#sct312784-bib-0090){ref-type="ref"} occurred partly through tunneling nanotubes and that this transfer could enhance phagocytic activity of macrophages by improving macrophage bioenergetics.[^91^](#sct312784-bib-0091){ref-type="ref"} Collectively, mitochondrial transfer from MSCs to alveolar epithelium and macrophages reduces lung injury and leads to an increase in fluid clearance and in phagocytic activity, respectively (Figure [2](#sct312784-fig-0002){ref-type="fig"}).

![Alveolar microenvironment in acute respiratory distress syndrome (ARDS) and MSC‐mediated repairing pathways. Alveolar injury is characterized by the impairment of endothelial and type I alveolar cell (pneumocyte) barrier, which eventually results in an intense accumulation of proteinaceous fluid (alveolar edema) and mononuclear cell (lymphocytes) infiltrates in interalveolar septa. Extravasated and/or resident MSCs can trigger a series of direct and indirect repairing mechanisms. A, Clearance of the increased alveolar edema can be induced by the release of KGF by enhancing sodium‐dependent alveolar fluid clearance through type II alveolar sodium channels. B, MSC‐released TSG6 decreases neutrophil functions, which directly affects improvement of the vascular endothelial and alveolar epithelial barriers. C, Resolution of inflammation can be further enhanced by the increased release of IL‐10 and decreased release of TNF‐α, which are mediated by LXA4 and PGE~2~. D, Increased epithelial repair in type II alveolar cells can be restored by the release of Ang1. (E, F, MSCs can also facilitate the phagocytosis of bacteria by the intra‐alveolar and interalveolar macrophages by releasing the antimicrobial peptide LL‐37 or by the transfer of extracellular vesicles to macrophages from MSCs. G, Additionally, MSCs can exert their actions through mitochondrial transfer to injured alveolar cells, thus increasing their ATP content, which would improve bioenergetics and increase alveolar epithelial function, improving surfactant release by type II alveolar cells. H, MSCs can degrade or inhibit ARDS‐induced fibrotic tissue formation (collagen fiber accumulation) to modulate the extracellular matrix by releasing MMPs and TIMPs. In MSC‐based therapies, infusion of auto/allogeneic MSCs are applied through two primary routes (ie, intravenous and intratracheal/intrabronchial). Ang1, angiopoietin‐1; IL, interleukin; KGF, keratinocyte growth factor; LXA4, lipoxin A4; MMP, matrix metalloproteinase; MSC, mesenchymal stem cell; PGE~2~, prostaglandin E2; TIMP, tissue inhibitor of matrix metalloproteinase; TNF, tumor necrosis factor; TSG6, TNF‐stimulated gene 6 protein. *Source:* Laffey and Matthay, 2017[^92^](#sct312784-bib-0092){ref-type="ref"}](SCT3-9999-na-g002){#sct312784-fig-0002}

10. EXPERIMENTAL AND CLINICAL USE OF MSC FOR ARDS {#sct312784-sec-0016}
=================================================

Because there is no specific therapy for ARDS, managing the clinical symptoms is solely supportive. Patients with moderate‐to‐severe ARDS benefits from protective ventilation and muscle relaxants. As such, alternative therapy regimens that can focus multiple mechanisms of injury, maintain or enhance host defenses to pathogens, and facilitate the lung repair process are a treatment goal. As discussed above, COVID‐19 progression mainly depends on the development of cytokine storm, which is triggered by the activation of macrophages and antigen‐presenting cells, thus alerting lymphocytes to the existence of virus that activates the synthesis of proinflammatory factors. In this regard, because of their potent immunoregulatory features, MSCs could have therapeutic benefits in patients with ARDS, who present hyperactivated T cells manifested by the sudden and extreme increase of several cytokines, which result in cytotoxic effects, mainly on the respiratory system. As indicated above, MSCs exert their constructive effects through the release of paracrine factors and EVs and transfer of mitochondria, all of which have anti‐inflammatory and regenerative effects on injured lung endothelium and alveolar pneumocytes (Figure [2](#sct312784-fig-0002){ref-type="fig"}; extensively reviewed by Laffey and Matthay[^92^](#sct312784-bib-0092){ref-type="ref"}). BM‐MSCs improved repair after ventilator‐induced lung injury, facilitated resolution of inflammation, and restored lung function and structure.[^93^](#sct312784-bib-0093){ref-type="ref"} The MSC‐derived EVs or conditioned media from MSCs diminished the injured alveolar epithelial permeability by restoring directional sodium and fluid transport in rats,[^94^](#sct312784-bib-0094){ref-type="ref"} restored cytokine‐injured cultured type II alveolar cells by the release of angiopoietin‐1,[^95^](#sct312784-bib-0095){ref-type="ref"} and improved alveolar fluid clearance in an ex vivo endotoxin‐injured lung model in humans, partly by the release of keratinocyte growth factor,[^96^](#sct312784-bib-0096){ref-type="ref"} potentially having a pivotal role in the resolution of ventilator‐induced lung injury.[^92^](#sct312784-bib-0092){ref-type="ref"} The MSC‐conditioned media rescued rats from bleomycin‐induced lung injury by relieving inflammatory markers and apoptosis and by reducing collagen‐rich scar tissue and fibrosis.[^97^](#sct312784-bib-0097){ref-type="ref"} MSCs also augmented the resolution of endotoxin‐induced lung injury in mice by the release of a lipid mediator, lipoxin A4.[^98^](#sct312784-bib-0098){ref-type="ref"} Additionally, MSC‐derived EVs diminished lung injury, reduced bacterial load, and enhanced survival in bacterial pneumonia in mice[^99^](#sct312784-bib-0099){ref-type="ref"} and improved airway compliance in humans.[^100^](#sct312784-bib-0100){ref-type="ref"}

As IL‐6 secreted by the macrophages is a central player in COVID‐19 and because it is induced by MSC‐derived PGE~2~, the blockage of IL‐6 through PGE~2~ inhibitors may have a suppressive role in cytokine storm in COVID‐19. Indeed, PGE~2~ regulates the production of a wide array of cytokines and upregulates both IL‐10 and IL‐6 in activated macrophages,[^101^](#sct312784-bib-0101){ref-type="ref"} which in turn triggers cytopathic effects of cytokine storm. PGE~2~ is also effective in elevating IL‐10 levels only when it is added to cells in which p38 kinase has been activated.[^101^](#sct312784-bib-0101){ref-type="ref"} However, the augmentation effect of PGE~2~ on IL‐6 levels is independent of p38 kinase activity, and p38 kinase inhibitors are able to inhibit IL‐6 production in activated macrophages by inhibiting PGE~2~ synthesis. Collectively, MSC‐derived PGE~2~ has a central role in controlling the COVID‐19‐induced IL‐6‐ and IL‐10‐mediated cytokine storm.

MSCs also have the potential of releasing antibacterial factors and therefore stimulating monocyte/macrophage phagocytosis.[^96^](#sct312784-bib-0096){ref-type="ref"} The secretion of LL‐37 (β‐cathelicidin), an antimicrobial peptide, contributed to the antibacterial properties of MSCs.[^102^](#sct312784-bib-0102){ref-type="ref"} Toll‐like receptors (TLRs) that are activated by viral RNA (TLR3) (as in COVID‐19) and viral unmethylated CpG‐DNA (TLR9) lead to downstream cell signaling pathways and result in MSC activation.[^103^](#sct312784-bib-0103){ref-type="ref"} However, mediators responsible for ameliorating respiratory viral‐induced lung injuries remain unclear.[^44^](#sct312784-bib-0044){ref-type="ref"} Another an important question that still remains to be resolved is whether MSC act directly against viral pathogens through antiviral proteins such as IFN‐stimulated genes, by stimulating antiviral T‐cell actions, or whether they are due to overall anti‐inflammatory actions.[^44^](#sct312784-bib-0044){ref-type="ref"}

As mentioned above, transfer of MSC mitochondria may also occur in the alveolar healing mechanism. Experiments in mice showed reduced endotoxin‐induced alveolar damage and increased survival, possibly via a gap junction protein (connexin‐43)‐dependent mechanism that augmented intracellular ATP levels in injured epithelial cells.[^89^](#sct312784-bib-0089){ref-type="ref"} More recently, mitochondrial transfer was demonstrated to occur from MSCs to macrophages,[^90^](#sct312784-bib-0090){ref-type="ref"} through tunneling nanotubes,[^91^](#sct312784-bib-0091){ref-type="ref"} which could enhance macrophage phagocytosis (Figure [2](#sct312784-fig-0002){ref-type="fig"}).

Given that MSC‐based interventions in experimental ARDS offers promising results, phase I/II clinical trials have been pursued to assess the efficacy and also safety of human MSC injections in patients with ARDS. A recent literature review by Qu et al[^104^](#sct312784-bib-0104){ref-type="ref"} found only nine trials (two were implemented in COVID‐19‐induced ARDS) in which the therapeutic success of MSCs from different sources was examined in 200 patients with ARDS over the last 30 years. All MSCs were allogeneic from bone marrow, umbilical cord stroma or blood, adipose tissue, or menstrual blood. The first study by Zheng et al in 2014 showed that no serious adverse events related to MSC administration were observed in 12 patients with ARDS.[^105^](#sct312784-bib-0105){ref-type="ref"} A single delivery of 1 × 10^6^ ADSCs per kilogram of body weight was transplanted intravenously. Length of hospital stay, ventilator‐free days, and ICU‐free days at day 28 after treatment were similar between the cell‐treated and control groups. Serum surfactant protein‐D levels at day 5 were significantly lower than those at day 0 in the MSC group. The authors concluded that administration of allogeneic ADSCs appeared to be safe and feasible in the treatment of ARDS. However, the clinical effect with the doses of MSCs used was weak, and further optimization of this strategy was needed. In a single case report (59‐year‐old man with a severe ARDS), Chang et al[^106^](#sct312784-bib-0106){ref-type="ref"} administered umbilical cord blood‐derived MSCs (1 × 10^6^/kg) via intratracheal route; they noted an immediate improvement in his mental status, his lung compliance, and his chest radiography over the course of 3 days. Wilson et al in 2015[^107^](#sct312784-bib-0107){ref-type="ref"} published the results of a dose‐escalation trial. Intravenous (IV) administration of allogeneic BM‐MSCs were tolerated well in nine patients with moderate‐to‐severe ARDS (each group consisting of three patients) who received a single delivery of 1, 5, or 10 × 10^6^ cells/kg. No specific therapeutic benefit was reported in this trial. In the same year, Simonson et al administered BM‐MSCs (single dose 2 × 10^6^ cells/kg) to two patients with severe ARDS and found that both patients exhibited improved lung function and survived multiorgan failure.[^108^](#sct312784-bib-0108){ref-type="ref"} More recently, the START study by Matthay et al demonstrated that no hemodynamic or respiratory adverse events related to allogeneic BM‐MSC infusion (single dose 10 × 10^6^ cells/kg) were observed over a 60‐day follow‐up period, and although the 28‐day mortality was higher in the MSC group compared with placebo, there was no significant difference between the groups.[^109^](#sct312784-bib-0109){ref-type="ref"} More recently, Yip et al[^110^](#sct312784-bib-0110){ref-type="ref"} investigated the therapeutic potential of single dose IV infusion of 1, 5, or 10 × 10^6^ UC‐MSCs/kg in nine moderate‐to‐severe cases of ARDS. They noted a trend of improvement in PaO~2~/FiO~2~ and shorter ventilator‐free ICU‐free days. Taken together, these clinical trials revealed improvements in radiographic findings, pulmonary function (lung compliance, tidal volumes, PaO~2~/FiO~2~ ratio, alveolo‐capillary injury), and inflammatory biomarker.[^104^](#sct312784-bib-0104){ref-type="ref"} However, there is still an urgent requirement for further assessment of the efficacy of MSCs, especially in COVID‐19‐induced ARDS cases. In addition, low mobilization of MSCs to the sites of injury and poor survival of transplanted MSCs in the harsh microenvironment are obstacles faced by clinical translation.[^111^](#sct312784-bib-0111){ref-type="ref"}

11. CLINICAL USE OF MSCs IN PATIENTS WITH COVID‐19 {#sct312784-sec-0017}
==================================================

As indicated above, cytokine storm leads to the advance of pulmonary damage and ARDS in patients with COVID‐19. Previous coronavirus pandemics (SARS and MERS) revealed that the immunosuppressive approach with corticosteroids was not routinely recommended and might exacerbate COVID‐19‐associated lung injury.[^112^](#sct312784-bib-0112){ref-type="ref"} IL‐6 blockade may benefit surviving patients with hyperinflammation. In some centers, including in China,[^113^](#sct312784-bib-0113){ref-type="ref"} multicenter, randomized controlled trials of tocilizumab (IL‐6 receptor blockade, licensed for cytokine release syndrome) are underway in patients with COVID‐19 pneumonia and elevated IL‐6.

Given that MSC trials were safe and slightly effective in patients with ARDS, at least in some cases and in tested doses, there is a growing demand for the application of MSC‐based interventions in patients with COVID‐19. Patients in the ICU would definitely be the first choice for an MSC‐based trial. As of June 5, 2020, two reports have appeared in the literature addressing the efficacy of completed (up to 2‐4 weeks\' follow‐up) MSC transplantations in patients with COVID‐19. The first report came from a group of physicians and scientists from China, who briefly described the clinical outcome of a 65‐year‐old female patient with COVID‐19.[^114^](#sct312784-bib-0114){ref-type="ref"} Her oxygen saturation was around 81% the day after hospital admission. According to the guidelines, she was treated with antiviral therapy of lopinavir/ritonavir, IFN‐α inhalation, and oseltamivir and IV injection of moxifloxacin, xuebijing, methylprednisolone, and immunoglobulin. Almost 10 days after admission, she developed severe organ failure. Upon cessation of the glucocorticoid and antiviral therapy, she received a triple‐IV infusion of allogenic UC‐MSCs (5 × 10^6^ cells each time). No obvious adverse effects were observed after injections. After the second administration, the serum bilirubin, CRP, and ALT/AST gradually decreased, along with the improvement of some vital signs. She was extubated, and lung improvement was verified in the chest CT images. Two days after the third infusion, her throat swabs were negative for SARS‐CoV‐2. At day 20 after admission, she was transferred out of the ICU.

The second report was a mini clinical trial from a multidisciplinary, multinational group of scientists and physicians.[^115^](#sct312784-bib-0115){ref-type="ref"} The researchers compared seven patients with COVID‐19 pneumonia (one critically severe, four serious, and two common; aged 18‐95 years) who were not responding to standard treatment. They received certified, Good Manufacturing Practices‐grade single dose 1 × 10^6^ UC‐MSC/kg[^116^](#sct312784-bib-0116){ref-type="ref"} as opposed to three patients in the control group who received no cells. All seven patients in the treatment group recovered in the 14‐day follow‐up. In the control group, one patient died, and another developed ARDS. Only one patient in the control group was stable. No complications were noted in the treatment group. Within a few days in the treated group, the oxygen saturation and biomarkers for inflammation and tissue injury such as CRP, AST, creatine kinase activity, and myoglobin normalized. Significant improvements were seen in the radiologic signs in the follow‐up CT scans of the lungs. The limitations of this study were the small sample size and short‐term follow‐up as well as the lack of statistical power and randomization.[^117^](#sct312784-bib-0117){ref-type="ref"} However, this mini trial also showed that infused MSCs remained negative for angiotensin‐converting enzyme 2, a cell surface receptor that is required for SARS‐CoV‐2 virus to attach to the alveolar epithelial cells,[^118^](#sct312784-bib-0118){ref-type="ref"} meaning that transplanted MSCs did not differentiate and remained free of virus.[^119^](#sct312784-bib-0119){ref-type="ref"}

In an extremely short time interval, as of June 5, 2020, 36 MSC trials for COVID‐19 were registered to [ClinicalTrials.gov](http://ClinicalTrials.gov), primarily aiming to rescue patients with severe or critical COVID‐19 (Table [2](#sct312784-tbl-0002){ref-type="table"}). Apparently, the number of trials will rise, because we are aware that in the corresponding author\'s country of residence, two phase II/III trials (enrolling 10 and 100 patients) and 25 single cases were recently approved by the Stem Cell Advisory and Review Board of the Ministry of Health (unpublished data). In the United States, the Food and Drug Administration approved stem cell therapy for COVID‐19 followed by the announcement of immediate actions of many cell manufacturing and treatment companies, some of which also publicized the patient recruitment. Although the full evidence for the success of MSC treatment in patients with COVID‐19 is still unavailable, we think that MSCs have a place in treatment and improvement for thousands of hopeless patients around the world in this widest pandemic to have ever happened in modern times. More recently, the American Academy of Stem Cell Physicians has announced recommendations for the treatment of COVID‐19, which it has sent to the director and representatives of the World Health Organization.[^120^](#sct312784-bib-0120){ref-type="ref"} Although the source of cells is different than MSCs, the treatment plan recommends the administration of umbilical cord blood‐derived mononuclear cells (1 × 10^6^ cells/kg) daily for hospitalized patients. Beside the aforementioned potential benefits of MSCs, it is also very important to point out that there is a good deal of concern about clinics offering unproven stem cell treatments for COVID‐19[^121^](#sct312784-bib-0121){ref-type="ref"}; as such, reviewers and oversight bodies will be looking for a systematic appraisal of evidence and risk‐benefit analysis of current trials.

###### 

MSC‐based clinical trials registered to [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov) database in COVID‐19 as of June 6, 2020

+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| ClinicalTrials identifier | Study design  | Current status          | Study location | MSC type                | Estimated enrollment/route of delivery | Primary outcome                                                                                                     |
+:==========================+:==============+:========================+:===============+:========================+:=======================================+:====================================================================================================================+
| NCT04348461               | Phase II      | Not yet recruiting      | Spain          | ADSC                    | 100/IV                                 | Survival rate                                                                                                       |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Safety assessed by adverse event rate                                                                               |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04366323               | Phase I/II    | Not yet recruiting      | Spain          | ADSC                    | 26/IV                                  | Safety assessed by adverse event rate                                                                               |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Survival rate                                                                                                       |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04352803               | Phase I       | Not yet recruiting      | United States  | ADSC                    | 20/IV                                  | Safety---Incidence of unexpected adverse events                                                                     |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04362189               | Phase II      | Not yet recruiting      | United States  | ADSC                    | 100/IV                                 | Change from baseline in levels of [d]{.smallcaps}‐dimer, interleukin‐6, C‐reactive protein, OI, PCR test SARS‐CoV‐2 |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04348435               | Phase II      | Enrolling by invitation | United States  | ADSC                    | 100/IV                                 | Incidence of hospitalization                                                                                        |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Incidence of associated symptoms                                                                                    |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04346368               | Phase I/II    | Not yet recruiting      | China          | BM‐MSC                  | 20/IV                                  | Changes of oxygenation index (PaO~2~/FiO~2~)                                                                        |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Side effects                                                                                                        |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04377334               | Phase II      | Not yet recruiting      | Germany        | BM‐MSC                  | 40/IV                                  | Improvement of lung injury score, 0‐16 points, severity increasing with higher points                               |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04397796               | Phase I       | Not yet recruiting      | United States  | BM‐MSC                  | 45/NA                                  | Incidence of adverse effects, mortality, and cause of death within 30 days of randomization                         |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Number of ventilator‐free days within 60 days of randomization                                                      |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04400032               | Phase I       | Not yet recruiting      | Canada         | BM‐MSC                  | 9/IV                                   | Number of participants alive by day 28                                                                              |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Number of participants with ventilator‐free days by day 28                                                          |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04336254               | Phase I/II    | Recruiting              | China          | DP‐MSC                  | 20/IV                                  | TTCI                                                                                                                |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Recovery of lung lesion                                                                                             |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Immune function                                                                                                     |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04302519               | Early phase I | Not yet recruiting      | China          | DP‐MSC                  | 24/IV                                  | Time to disappearance of ground‐glass shadow in the lungs                                                           |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04276987               | phase I       | Not yet recruiting      | China          | MSC‐derived exosomes    | 30/aerosol inhalation                  | Adverse effects and severe adverse reactions                                                                        |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | TTCI                                                                                                                |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04315987               | Phase II      | Not yet recruiting      | Brazil         | NestaCell               | 90/IV                                  | Time to disappearance of ground‐glass shadow in the lungs                                                           |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04389450               | Phase II      | Not yet recruiting      | United States  | PLX‐PAD MSC             | 140/IM                                 | Number of ventilator‐free days by day 28                                                                            |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04339660               | Phase I/II    | Recruiting              | China          | UC‐MSC                  | 30/IV                                  | The immune function                                                                                                 |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Increase in blood oxygen saturation                                                                                 |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04273646               | NA            | Not yet recruiting      | China          | UC‐MSC                  | 48/IV                                  | Pneumonia severity index                                                                                            |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Oxygenation index (PaO~2~/FiO~2~)                                                                                   |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04269525               | Phase II      | Recruiting              | China          | UC‐MSC                  | 10/IV                                  | Oxygenation index (PaO~2~/FiO~2~)                                                                                   |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04333368               | Phase I/II    | Recruiting              | France         | UC‐MSC                  | 40/IV                                  | Respiratory efficacy evaluated by the increase in PaO~2~/FiO~2~                                                     |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT03042143               | Phase I/II    | Recruiting              | United Kingdom | UC‐MSC (CD362 enriched) | 75/NA                                  | OI                                                                                                                  |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Incidence of serious adverse events                                                                                 |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04355728               | Phase I/II    | Recruiting              | United States  | UC‐MSC                  | 24/IV                                  | Incidence of prespecified infusion‐associated adverse events                                                        |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Incidence of severe adverse events                                                                                  |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04366271               | Phase II      | Recruiting              | Spain          | UC‐MSC                  | 106/IV                                 | Mortality due to lung involvement at 28 days of treatment                                                           |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04398303               | Phase I/II    | Not yet recruiting      | United States  | UC‐MSC                  | 70/IV                                  | Mortality at day 30                                                                                                 |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04313322               | Phase I       | Recruiting              | Jordan         | WJ‐MSC                  | 5/IV                                   | Clinical improvement                                                                                                |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Improvement in CT Scan                                                                                              |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04390152               | Phase I/II    | Not yet recruiting      | Colombia       | WJ‐MSC                  | 40/IV                                  | Evaluation of efficacy of cells defined by mortality at 28 days of application                                      |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04390139               | Phase I/II    | Recruiting              | Spain          | WJ‐MSC                  | 30/EV                                  | All‐cause mortality at day 28, number of patients who died                                                          |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04382547               | Phase I/II    | Enrolling by invitation | Belarus        | OMD‐MSC                 | 40/NA                                  | Number of cured patients                                                                                            |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Number of patients with treatment‐related adverse events                                                            |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04349631               | Phase II      | Enrolling by invitation | United States  | ADSC                    | 56/IV                                  | Incidence of hospitalization                                                                                        |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Incidence of associated symptoms                                                                                    |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04416139               | Phase II      | Recruiting              | Mexico         | NR                      | 10/IV                                  | PaO~2~/FiO~2~ ratio                                                                                                 |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Heart rate per minute                                                                                               |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Respiratory rate per minute                                                                                         |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Changes in body temperature                                                                                         |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04371601               | Early phase I | Active, not recruiting  | China          | NR                      | 60/NA                                  | Changes of oxygenation index (PaO~2~/FiO~2~), blood gas test                                                        |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04345601               | Early phase I | Not yet recruiting      | United States  | NR                      | 30/IV                                  | Incidence of unexpected adverse events                                                                              |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Improved oxygen saturations ≥93%                                                                                    |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04288102               | Phase II      | Recruiting              | China          | NR                      | 90/IV                                  | Size of lesion area and severity of pulmonary fibrosis by chest CT                                                  |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04252118               | Phase I       | Recruiting              | China          | NR                      | 20/IV                                  | Size of lesion area by chest radiography or CT                                                                      |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Side effects in the MSC treatment group                                                                             |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04366063               | Phase II/III  | Recruiting              | Iran           | NR                      | 60/IV                                  | Adverse events assessment                                                                                           |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Blood oxygen saturation                                                                                             |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04392778               | Phase I/II    | Recruiting              | Turkey         | NR                      | 30/NA                                  | Improvement of clinical symptoms                                                                                    |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04361942               | Phase II      | Recruiting              | Spain          | NR                      | 24/IV                                  | Proportion of patients who have achieved clinical response                                                          |
|                           |               |                         |                |                         |                                        |                                                                                                                     |
|                           |               |                         |                |                         |                                        | Proportion of patients who have achieved radiological responses                                                     |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+
| NCT04371393               | Phase III     | Recruiting              | United States  | NR                      | 300/IV                                 | Number of all‐cause mortalities within 30 days of randomization                                                     |
+---------------------------+---------------+-------------------------+----------------+-------------------------+----------------------------------------+---------------------------------------------------------------------------------------------------------------------+

Abbreviations: ADSC, adipose tissue--derived stem cell; BM‐MSC, bone marrow mesenchymal stem cell; CT, computed tomography; DP‐MSC, dental pulp mesenchymal stem cell; EV, extracellular vesicle; FiO~2~, fraction of inspired oxygen; IV, intravenous; MSC, mesenchymal stem cell; NA, not available; NR, not reported; OI, oxygenation index; OMD‐MSC, olfactory mucosa‐derived MSC; PaO~2~, partial pressure of oxygen; PCR, polymerase chain reaction; PLX‐PAD, placental mesenchymal‐like adherent stromal cells; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; TTCI, time to clinical improvement; UC‐MSC, umbilical cord mesenchymal stem cell; WJ‐MSC, Wharton\'s jelly mesenchymal stem cell.

12. CONCLUSION {#sct312784-sec-0018}
==============

Besides the central question regarding whether MSC therapy would be a proven stem cell therapy for patients with COVID‐19, obviously, there are still many unanswered critical questions, such as (a) which source of MSCs would be more beneficial; (b) with what cell dose and how many times should MSCs be administered; (c) what is the best route for the cell administration (IV or intratracheal/intrabronchial); (d) what is the best time to intervene with MSCs in patients with COVID‐19; (e) what would be the optimal follow‐up time for cell‐treated patients to confirm the efficacy of a given therapy schema; and (f) is it beneficial to add any drugs to enhance or support the MSC treatment? The answers to some of the above questions largely remain obscured by the lack of comparison studies. Regarding the route of cell administration, the IV route seems to be the best choice for greater cell survival, practicability of bedside application, and likelihood of paracrine effect exertion. On the other hand, one of the main problems of the MSC‐based therapeutic interventions is that high expectations based on the strong therapeutic effect in preclinical models do not match up with the reality of low efficacy of MSCs in clinical trials. One explanation of this might be that real human subjects (patients) present with much more heterogeneous disease states and varying conditions than inbred animal strains; therefore, we need much better understanding of the patient populations, aiming MSC therapy at those who will be most likely to respond. This problem is crucially relevant to patients with COVID‐19‐induced ARDS.

CONFLICT OF INTEREST {#sct312784-sec-0021}
====================

The authors declared no potential conflicts of interest.

AUTHOR CONTRIBUTIONS {#sct312784-sec-0020}
====================

A.C.: conception and design, manuscript writing; H.C.: manuscript writing.

The authors would like to thank to Drs Ferda Topal Celikkan and Birol Ay for their critical and constructive criticisms on the manuscript and the academic members and staff of the Stem Cell Advisory and Review Board of the Turkish Ministry of Health for sharing the information regarding the clinical status of the first nine MSC‐treated patients with COVID‐19. No financial support has been provided to write and publish the manuscript.

DATA AVAILABILITY STATEMENT {#sct312784-sec-0023}
===========================

Data sharing is not applicable to this article as no new data were created or analyzed in this study.
